DxU Iris Nominated for the SelectScience Scientists' Choice Awards®

Laboratory scientists around the world are invited to vote for the Best New Clinical Product of 2021.
DxU Iris Nominated for the SelectScience Scientists' Choice Awards®

Best New Clinical Product of 2021

SelectScience’s annual Scientists' Choice Awards celebrates the most innovative and effective technologies of the past year chosen by the people who actually use them – the scientists. Scientists worldwide have the opportunity to recognize the instruments, assays, tools and consumables that have made the most difference to their work.

Thanks to our loyal customers, we’re delighted to announce the DxU Iris Workcell Automated Urinalysis Solution has been nominated in the Best New Clinical Product of 2021 category!

The innovative and reliable DxU Iris Workcell Automated Urinalysis Solution is streamlining workflow, reducing manual microscopic review, and standardizing high-throughput processing. Featuring load-and-go, walkaway capabilities and Edit-Free Release technology, the DxU Iris takes the interruptions out of your urinalysis workflow.

Cast your vote

Voting is now open. Take a moment to view the shortlists, as nominated by clinical scientists and healthcare professionals worldwide, and cast your vote for the Best New Clinical Product.

Voting closes Tuesday, July 19, 2022. All scientists who vote for Best New Clinical Products will be entered into a drawing for a chance to win a $500/£400/450 € Amazon Gift Card from SelectScience.

Editorial Team
Editorial Team
The Beckman Coulter editorial team brings you timely news and resources focused on elevating clinical laboratory performance and advancing patient care.

Related Articles

Advancing Clinical Capabilities to Empower Better Outcomes

Advancing Clinical Capabilities to Empower Better Outcomes

Discover how our philosophy of Advancing Clinical Capabilities is helping us deliver greater insights in areas like women’s health, cardiovascular disease, infectious disease, and beyond.
Rethinking Heart Failure Diagnosis in an Era of Rising Obesity

Rethinking Heart Failure Diagnosis in an Era of Rising Obesity

As obesity rates climb toward 50% of the U.S. population, clinicians face a growing diagnostic challenge: obesity is associated with lower NT-proBNP levels, potentially masking heart failure in the patients most at risk.
The Global Burden of Cardiovascular Disease in Women

The Global Burden of Cardiovascular Disease in Women

Based on "Women's Hearts: Biomarkers for Precision-based Care," a webinar with Dr. Emily Lau, MD, MPH. Dr. Lau is a cardiologist and public health expert specializing in cardiovascular disease prevention, heart failure, and women’s cardiac health. Her research focuses on risk prediction, sex-based differences in cardiovascular disease, and strategies to improve outcomes through evidence-based care.